Jorge Augusto Alcacio-Mendoza

Dr. Jorge Augusto Alcacio-Mendoza

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2025 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
JAJorge Augusto Alcacio-Mendoza
Jorge Augusto Alcacio-Mendoza
HLHorst Emanuel Lagos-Beitz
Horst Emanuel Lagos-Beitz
PCPetra Betsabé Carreño-Hinojosa
Petra Betsabé Carreño-Hinojosa
YBYoztinn Bernal-Benitez
Yoztinn Bernal-Benitez
GMGuillermo H Martínez-Delgado
Guillermo H Martínez-Delgado
FRFrancisco T. Rodríguez-Covarrubias
Francisco T. Rodríguez-Covarrubias

11 September 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SPSilvia Proietti
Silvia Proietti
CGCristian Axel Hernandez Gaytan
Cristian Axel Hernandez Gaytan
JAJorge Augusto Alcacio-Mendoza
Jorge Augusto Alcacio-Mendoza
FGFranco Gaboardi
Franco Gaboardi
GGGuido Giusti
Guido Giusti
Background & Objectives: Laser lithotripsy is the standard energy source for mini-percutaneous nephrolithotomy (mini-PCNL). Although Holmium:YAG (Ho:YAG), Thulium Fiber Laser (TFL), and pulsed Thulium:YAG (p-Tm:YAG) are currently available for clinical use, direct comparisons among all three laser technologies are lacking. This study aimed to compare the efficacy, safety, and procedural performance of Ho:YAG, TFL, and p-Tm:YAG during mini-PCNL. The primary endpoint was the stone-free rate (SFR). Secondary outcomes included complications, operative time, lasing time, total energy delivered, and laser-related procedural metrics. Methods: Consecutive patients treated with p-Tm:YAG during mini-PCNL for renal stones were prospectively enrolled and compared with two cohorts from our institutional database treated with Ho:YAG or TFL. All procedures were performed using the same mini-PCNL technique and predefined laser settings selected to achieve the closest technically feasible match among the three platforms. Results: Ninety patients were included (30 per group). No significant differences in SFR were observed among Ho:YAG, TFL, and p-Tm:YAG (p = 0.93), or in overall complication rates (p = 0.93). After adjusting for stone volume, density, composition, and location, the laser platform was not independently associated with SFR, whereas stone volume was the only independent predictor of stone-free status. TFL exhibited a significantly longer operative time than Ho:YAG and a longer lasing time than both Ho:YAG and p-Tm:YAG, and was associated with greater total energy delivery, lower ablation efficiency, and lower ablation speed. Conversely, p-Tm:YAG demonstrated a significantly shorter lasing time than TFL and an ablation efficiency similar to that of Ho:YAG, with lasing time and ablation speed values between those observed with Ho:YAG and TFL under the evaluated settings. Laser efficacy did not differ significantly among the three groups. Conclusions: No significant differences in stone-free or safety outcomes were observed among the three laser platforms in mini-PCNL. Although significant differences were observed in lasing time, ablation speed, and energy utilization, p-Tm:YAG demonstrated an intermediate procedural profile under the operating parameters evaluated in this study. Overall, the present findings suggest that p-Tm:YAG represents a feasible treatment option for mini-PCNL, although larger randomized studies are needed before firm conclusions regarding relative platform performance can be drawn.

23 July 2026 in The Prostate
Verified
Journal Article
Closed access
CGCarlos Alexis González‐Martínez
Carlos Alexis González‐Martínez
JAJorge Augusto Alcacio-Mendoza
Jorge Augusto Alcacio-Mendoza
RHRodrigo Hernández‐Ramírez
Rodrigo Hernández‐Ramírez
HLHorst Emanuel Lagos‐Beitz
Horst Emanuel Lagos‐Beitz
GTGerardo Tena‐González‐Méndez
Gerardo Tena‐González‐Méndez
RCRicardo Alonso Castillejos‐Molina
Ricardo Alonso Castillejos‐Molina

2 June 2025 in Revista Mexicana de Urología
Verified
Journal Article
Open access
PDF file
VCVíctor Enrique Corona-Montes
Víctor Enrique Corona-Montes
HRHéctor Hernández Remess
Héctor Hernández Remess
JGJesús David Castrejón García
Jesús David Castrejón García
JAJorge Augusto Alcacio-Mendoza
Jorge Augusto Alcacio-Mendoza
JNJesús Emmanuel Rosas Nava
Jesús Emmanuel Rosas Nava
JCJosé Manuel Rodríguez González Cobián
José Manuel Rodríguez González Cobián
Introduction: Bilateral testicular tumors are very rare, representing between 1 % and 5 % of all testicular germ cell tumors (TGCT). The vast majority of primary bilateral TGCTs are metachronous, while synchronous tumors account for approximately 0.5 % to 1 % of all cases. Synchronous tumors mostly share the same histological pattern, predominantly seminoma, and synchronous bilateral TGCTs (SBTGCT) with discordant subtypes are extremely rare. Relevance & discussion: The atypical presentation of synchronous bilateral testicular carcinoma with metastatic histopathological discordance poses a therapeutic challenge. Historically, the pathogenesis behind the development of synchronous bilateral TGCTs has been a controversial and still undetermined topic. Apparently are result from separate oncological mechanisms and occur as the development of two independent primary tumors. Clinical case: A 19-year-old male presented with swelling in the left side of the neck. The biopsy reported an embryonal carcinoma, confirmed by ultrasound and tumor markers, revealing bilateral testicular tumors. A left radical orchiectomy was performed, resulting in a mixed germ cell tumor, followed by a right radical orchiectomy after chemotherapy, which yielded a teratoma. Conclusion: It is known that synchronous primary bilateral testicular germ cell tumors (TGCTs) typically present with similar histology; however, we discuss discordant histology presentations.